FREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS
Please find below our response to some frequently asked questions. If you have more detailed questions, feel free to contact us or take a look at our Technology page.
PRIME is a clinical stage research and development company developing next generation vaccines both, for humans and animals. We offer technology licenses for existing and customer-specific vaccination vectors for the prevention and therapy of infectious diseases and cancer.
Our vaccines are based on an attenuated Orf virus (ORFV), which is proven to be safe and well tolerated by humans. We utilize this particular virus as a platform technology to design and generate vaccination vectors comprising tumor- or pathogen-specific information. These vaccination vectors deliver the information to specifically activate the immune system and prevent from, or treat an existing disease. Further, the ORFV platform allows for the integration of accessory information that can further increase the immune response (e.g. cytokines, activation signals, and/or checkpoint antibodies in a modular design).
PRIME’s safe platform technology combines the advantages of alternative vaccine technologies and adds even more:
PVT has followed an extensive testing strategy to identify the most potent, multivalent vaccine candidate to address the COVID-19 pandemic. Preclinical data has shown our lead vaccine candidate Prime-2-CoV to induce highly potent immune responses against all encoded antigens and protection to challenge infection in several model organisms including non-human primates. Currently, the vaccine is being tested in phase I clinical trials.